 REDWOOD CITY, Calif., April 23, 2021 GLOBE NEWSWIRE -- Coherus BioSciences, Inc. Nasdaq: CHRS has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data Monitoring Committee of the JUPITER-06 clinical trial has determined that toripalimab, an anti-PD-1 monoclonal antibody, in combination with paclitaxelcisplatin as first-line treatment for patients with advanced esophageal squamous cell carcinoma ESCC, has achieved the pre-specified primary endpoints of progression free survival PFS and overall survival OS at the interim analysis. JUPITER-06 is a randomized, double-blind, placebo-controlled, multi-center, phase 3 clinical trial initiated in 2019 with 514 patients enrolled. 